Japan Lifeline Co Ltd

Chart & Performance

D1W1MN

P/E

12.72

P/S

1.86

EPS

107.20

Div Yield, %

3.10%

Shrs. gr., 5y

-1.13%

Rev. gr., 5y

2.45%

Revenues

51.38b

-0.71%

Net income

7.52b

+9.06%

CFO

6.92b

-38.24%

Dividend

Mar 28, 20250 JPY/sh

Earnings

Jan 31, 2025

Profile

Japan Lifeline Co., Ltd., a medical device company, develops, produces, imports, distributes, and trades in cardiovascular related medical devices in Japan. The company's cardiac rhythm management products include cardiac pacemakers, implantable cardioverter defibrillators, subcutaneous implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators and pacemakers, automated external defibrillators, and cardiopulmonary resuscitation support devices; and electrophysiology/ablation products comprise electrophysiological and ablation catheters, irrigated tip ablation catheters, endoscopic balloon ablation systems, esophageal temperature monitoring systems, internal atrial cardioversion systems, and radio-frequency transseptal needles. Its cardiovascular and endografting products consist of vascular and open stent grafts, and abdominal stent-grafts; and transvascular intervention products include PTCA and PTA guide wires, PTCA balloon catheters, radiofrequency wires, and atrial septal defect closure devices. The company offers gastrointestinal intervention products that consist of radiofrequency ablation systems, self-expandable colonic stents, and endoscopic guidewires. Japan Lifeline Co., Ltd. was incorporated in 1981 and is headquartered in Tokyo, Japan.

URL

https://www.jll.co.jp/

IPO date

Dec 08, 1997

Employees

1,166

Domiciled in

Incorporated in

Valuation

Order:

Title JPY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title JPY in thousands, except ratios and share amounts	2024‑03	2023‑03	2022‑03	2021‑03	2020‑03	2019‑03	2018‑03	2017‑03	2016‑03	2015‑03
Income
Revenues	51,384,000 -0.71%	51,750,000 0.55%	51,469,000 0.36%
Cost of revenue	24,564,000	25,571,000	25,885,000
Unusual Expense (Income)
NOPBT	26,820,000	26,179,000	25,584,000
NOPBT Margin	52.20%	50.59%	49.71%
Operating Taxes	3,060,000	2,897,000	2,556,000
Tax Rate	11.41%	11.07%	9.99%
NOPAT	23,760,000	23,282,000	23,028,000
Net income	7,515,000 9.06%	6,891,000 -7.92%	7,484,000 274.20%
Dividends	(2,965,000)	(3,050,000)	(3,952,000)
Dividend yield	3.20%	4.26%	4.79%
Proceeds from repurchase of equity	(3,319,000)	(2,049,000)	(444,000)
BB yield	3.58%	2.86%	0.54%
Debt
Debt current	4,061,000	5,568,000	6,390,000
Long-term debt	1,026,000	1,698,000	2,398,000
Deferred revenue		(59,000)	(48,000)
Other long-term liabilities	660,000	2,947,000	2,668,000
Net debt	(16,347,000)	(18,208,000)	(16,150,000)
Cash flow
Cash from operating activities	6,918,000	11,201,000	10,246,000
CAPEX	(2,123,000)	(1,729,000)	(1,858,000)
Cash from investing activities	(4,056,000)	(2,461,000)	(1,131,000)
Cash from financing activities	(8,553,000)	(6,476,000)	(6,804,000)
FCF	20,900,000	25,055,000	23,739,000
Balance
Cash	12,669,000	18,357,000	16,058,000
Long term investments	8,765,000	7,117,000	8,880,000
Excess cash	18,864,800	22,886,500	22,364,550
Stockholders' equity	49,991,000	44,856,000	41,210,000
Invested Capital	44,530,200	41,297,500	41,466,450
ROIC	55.37%	56.26%	56.45%
ROCE	42.31%	40.75%	40.05%
EV
Common stock shares outstanding	76,122	78,116	80,367
Price	1,218.00 32.97%	916.00 -10.81%	1,027.00 -26.70%
Market cap	92,716,596 29.58%	71,554,256 -13.31%	82,536,909 -26.65%
EV	76,369,596	53,415,256	66,386,909
EBITDA	28,609,000	27,745,000	27,195,000
EV/EBITDA	2.67	1.93	2.44
Interest	26,000	34,000	76,000
Interest/NOPBT	0.10%	0.13%	0.30%